JCCT Appoints New CEO To Accelerate Growth And Innovation
"JCCT has a strong foundation and an exceptional team," said Dan White, CEO. "I'm honored to lead the organization into this exciting new chapter, expanding our network and therapeutic coverage while deepening our impact in clinical research."
JCCT conducts clinical trials across a broad spectrum of therapeutic areas, including vaccines, nephrology, and cardiometabolic diseases-backed by deep expertise in first‐in‐human studies, allergy, cardiovascular, endocrine/metabolism, infectious diseases, and more. With the recent addition of a site in Kansas City, MO, and new affiliations with leading physician groups, the company is well-positioned for continued growth and expanded impact in the clinical research industry.
"We've spent the last 20 years building JCCT into a trusted research partner," said Nathan Arthur, Co-Founder. "Dan brings the leadership and experience needed to take it to the next level."
"Dan shares our commitment to science, innovation, and people," added Mazen Zari, Co-Founder. "We are confident in his ability to guide JCCT's continued growth and success."
"JCCT's future is bright," said Board Member Karen Winterhof. "Dan's leadership, paired with the co-founders' continued strategic involvement, ensures continuity with fresh energy and direction."
About Johnson County Clin Trials
Founded in 2005, Johnson County Clin Trials is dedicated to advancing modern medicine through scientific disease prevention and clinical excellence. Backed by a growing site network and a steadfast commitment to high-quality research, JCCT delivers dependable data and outstanding care to every study participant.
To learn more, visit .
SOURCE Johnson County Clin Trials
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment